A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan.
Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.
Nature Communications
Berko, Esther R ER; Witek, Gabriela M GM; Matkar, Smita S; Petrova, Zaritza O ZO; Wu, Megan A MA; Smith, Courtney M CM; Daniels, Alex A; Kalna, Joshua J; Kennedy, Annie A; Gostuski, Ivan I; Casey, Colleen C; Krytska, Kateryna K; Gerelus, Mark M; Pavlick, Dean D; Ghazarian, Susan S; Park, Julie R JR; Marachelian, Araz A; Maris, John M JM; Goldsmith, Kelly C KC; Radhakrishnan, Ravi R; Lemmon, Mark A MA; Mossé, Yaël P YP
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
Nature Medicine
Goldsmith, Kelly C KC; Park, Julie R JR; Kayser, Kimberly K; Malvar, Jemily J; Chi, Yueh-Yun YY; Groshen, Susan G SG; Villablanca, Judith G JG; Krytska, Kateryna K; Lai, Lillian M LM; Acharya, Patricia T PT; Goodarzian, Fariba F; Pawel, Bruce B; Shimada, Hiroyuki H; Ghazarian, Susan S; States, Lisa L; Marshall, Lynley L; Chesler, Louis L; Granger, Meaghan M; Desai, Ami V AV; Mody, Rajen R; Morgenstern, Daniel A DA; Shusterman, Suzanne S; Macy, Margaret E ME; Pinto, Navin N; Schleiermacher, Gudrun G; Vo, Kieuhoa K; Thurm, Holger C HC; Chen, Joseph J; Liyanage, Marlon M; Peltz, Gerson G; Matthay, Katherine K KK; Berko, Esther R ER; Maris, John M JM; Marachelian, Araz A; Mossé, Yael P YP
Therapeutic Monitoring of Orally Administered, Small-Molecule Anticancer Medications with Tumor-Specific Cellular Protein Targets in Peripheral Fluid Spaces-A Review.
Pharmaceutics
Köllő, Zoltán Z; Garami, Miklós M; Vincze, István I; Vásárhelyi, Barna B; Karvaly, Gellért Balázs GB
Highly sensitive liquid biopsy Duplex sequencing complements tissue biopsy to enhance detection of clinically relevant genetic variants.
Frontiers In Oncology
Hallermayr, Ariane A; Neuhann, Teresa M TM; Steinke-Lange, Verena V; Scharf, Florentine F; Laner, Andreas A; Ewald, Roland R; Liesfeld, Ben B; Holinski-Feder, Elke E; Pickl, Julia M A JMA
Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort.
Translational Lung Cancer Research
Zou, Zihua Z; Gu, Yangchun Y; Liang, Li L; Hao, Xuezhi X; Fan, Chengjuan C; Xin, Tao T; Zhao, Songchen S; Liu, Ziling Z; Guo, Ye Y; Ma, Kewei K; Li, Haojing H; Zhang, Cuiying C; Shan, Li L; Zhang, Yan Y; Dong, Guilan G; Peng, Yumei Y; Shen, Fangfang F; Song, Xia X; Christopoulos, Petros P; van der Wekken, Anthonie J AJ; Okuda, Katsuhiro K; Ekman, Simon S; Xing, Puyuan P; Li, Junling J
Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501).
Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors.
Cancers
Verdura, Sara S; Encinar, Jose Antonio JA; Teixidor, Eduard E; Segura-Carretero, Antonio A; Micol, Vicente V; Cuyàs, Elisabet E; Bosch-Barrera, Joaquim J; Menendez, Javier A JA
Classical ALK G1202R resistance mutation was identified in a lung adenocarcinoma patient with rare LOC388942-ALK fusion after sequential treatment with ALK-TKIs and anlotinib: a case report.